Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Affiliations

¹ Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden.
² Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden. Electronic address: anders.bjartell@med.lu.se.

Comment

Aseem Undvall Anand et al. Eur Urol. 2015 Feb.

. 2015 Feb;67(2):349-50.

doi: 10.1016/j.eururo.2014.11.020.

¹ Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden.
² Department of Urology, Skåne University Hospital Malmö, Malmö, Sweden; Department of Clinical Sciences Malmö, Division of Urological Cancers, Lund University, Lund, Sweden. Electronic address: anders.bjartell@med.lu.se.

No abstract available

Comment on

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.